Država: Kanada
Jezik: angleščina
Source: Health Canada
GABAPENTIN
SIVEM PHARMACEUTICALS ULC
N02BF01
GABAPENTIN
100MG
CAPSULE
GABAPENTIN 100MG
ORAL
100/500
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0125929001; AHFS:
APPROVED
2012-06-01
_Product Monograph GABAPENTIN_ _Page 1 of 30_ _ _ PRODUCT MONOGRAPH PR GABAPENTIN Gabapentin Capsules (Manufacturer’s Standard) 100 mg, 300 mg and 400 mg ANTIEPILEPTIC AGENT Sivem Pharmaceuticals ULC 4705 Dobrin Street, Saint-Laurent, Quebec H4R 2P7 www.sivem.ca Date of Revision: August 20, 2020 Submission Control No.: 242233 _Product Monograph GABAPENTIN_ _Page 2 of 30_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 8 DRUG INTERACTIONS ......................................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................................... 15 OVERDOSAGE ........................................................................................................................ 17 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 17 STORAGE AND STABILITY ................................................................................................. 20 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 20 PART II: SCIENTIFIC INFORMATION ............................................................................... 21 PHARMACEUTICAL INFORMATION ................................................................................. 21 CLINICAL TRIALS ...... Preberite celoten dokument